Treatment with conjugated syd985 cancer patients resistant to treatment with t-dm1

摘要

p This Invention relates to Antibody Drug conjugate (ADC) duocarmicina trastuzumab containing VC - dry - duba syd985) for the treatment of patients with HER2 + IHC 32 + / HER2 IHC and Fish positive resistant to treatment with Trastuzumab Emtansine (t-dm1), specifically patients with breast cancer resistant to treatment with t-dm1. / p